Biosergen Feed

	Tid*
2025-03-31	N/A	Bokslutskommuniké 2024
2024-11-08	-	Kvartalsrapport 2024-Q3
2024-08-30	-	Kvartalsrapport 2024-Q2
2024-06-14	-	Årsstämma
2024-06-03	-	X-dag ordinarie utdelning BIOSGN 0.00 SEK
2024-05-31	-	Kvartalsrapport 2024-Q1
2024-02-29	-	Bokslutskommuniké 2023
2023-11-30	-	Kvartalsrapport 2023-Q3
2023-08-31	-	Kvartalsrapport 2023-Q2
2023-05-31	-	Årsstämma
2023-05-31	-	Kvartalsrapport 2023-Q1
2023-05-02	-	X-dag ordinarie utdelning BIOSGN 0.00 SEK
2023-03-31	-	Bokslutskommuniké 2022
2022-11-30	-	Kvartalsrapport 2022-Q3
2022-08-31	-	Kvartalsrapport 2022-Q2
2022-06-30	-	Årsstämma
2022-05-31	-	Kvartalsrapport 2022-Q1
2022-04-29	-	X-dag ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31	-	Bokslutskommuniké 2021
2021-11-30	-	Kvartalsrapport 2021-Q3

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Bioteknik

2024-12-20 13:40:03 Biosergen AB: Biosergen Agrees to Accelerated Dosing Escalation in Ongoing Second Cohort of Clinical Trial 0,50 SEK | -0,79% | 0,97 MSEK

2024-12-20 13:40:03 Biosergen AB: Biosergen samtycker till accelererad dosökning i den pågående andra kohorten i den kliniska prövningen 0,50 SEK | -0,79% | 0,97 MSEK

2024-12-05 11:29:49 Biosergen AB: Biosergen beslutar om ersättningsemissions till garanter i samband med att nyttjandeperioden för teckningsoptioner av serie TO3 löpt ut 0,66 SEK | -3,53% | 0,10 MSEK

2024-12-05 11:29:49 Biosergen AB: Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 0,66 SEK | -3,53% | 0,10 MSEK

2024-12-03 20:22:00 Biosergen AB conducts a directed share issue to underwriters in connection with the completed exercise period for warrants of series TO3 0,68 SEK | -5,82% | 0,11 MSEK

2024-12-03 20:19:23 Biosergen AB tillförs cirka 44,9 MSEK genom teckningsoptioner av serie TO3 0,68 SEK | -5,82% | 0,11 MSEK

2024-12-03 20:19:23 Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 0,68 SEK | -5,82% | 0,11 MSEK

2024-11-26 11:57:15 Biosergen AB: Biosergen doserar de första patienterna i den andra kohorten i den kliniska studien BSG005 för behandling av livshotande svampinfektioner 0,73 SEK | +17,04% | 0,26 MSEK

2024-11-26 11:57:15 Biosergen AB: Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections 0,73 SEK | +17,04% | 0,26 MSEK

2024-11-26 11:01:09 Sista dag för handel med teckningsoptionerna av serie TO3 i Biosergen AB är idag, den 26 november 2024 0,73 SEK | +17,04% | 0,26 MSEK

2024-11-26 11:01:09 The last day of trading with the warrants of series TO3 in Biosergen AB is today, November 26, 2024 0,73 SEK | +17,04% | 0,26 MSEK

2024-11-21 14:16:37 Biosergen AB: Biosergen Releases Interview with Principal Investigator Dr. Pawan Singh on Drug-Resistant Fungal Infections and BSG005 0,62 SEK | -3,45% | 0,06 MSEK

2024-11-18 08:30:00 Biosergen AB: Biosergen has secured 100 percent of the warrants of series TO3 approximately SEK 44.9 million 0,66 SEK | -0,30% | 0,26 MSEK

2024-11-18 08:30:00 Biosergen AB: Biosergen har säkerställt 100 procent av teckningsoptionerna av serie TO3 om cirka 44,9 MSEK 0,66 SEK | -0,30% | 0,26 MSEK

2024-11-18 08:00:00 The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49 0,66 SEK | -0,30% | 0,26 MSEK

2024-11-18 08:00:00 Teckningskursen för nyttjandet av teckningsoptioner av serie TO3 i Biosergen AB har fastställts till 0,49 SEK 0,66 SEK | -0,30% | 0,26 MSEK

2024-11-08 08:30:00 Biosergen AB: Biosergen publicerar delårsrapport för tredje kvartalet 2024 0,73 SEK | +4,87% | 0,16 MSEK

2024-11-08 08:30:00 Biosergen AB: Biosergen publishes interim report for third quarter 2024 0,73 SEK | +4,87% | 0,16 MSEK

2024-11-07 08:30:00 Biosergen AB: Biosergen Announces Safety Committee Approval to Proceed with Dose Escalation in Second Cohort for BSG005 Clinical Trial 0,70 SEK | -1,69% | 0,15 MSEK

2024-11-07 08:30:00 Biosergen AB: Biosergen meddelar säkerhetskommitténs godkännande att fortsätta med doseskalering i den andra kohorten i den kliniska studien BSG005 0,70 SEK | -1,69% | 0,15 MSEK

2024-10-31 17:30:00 Biosergen AB: Biosergen slutför den första kohorten i den kliniska studien BSG005, som visar lovande potential vid läkemedelsresistenta svampinfektioner 0,72 SEK | -0,83% | 0,46 MSEK

2024-10-31 17:30:00 Biosergen AB: Biosergen Completes First Cohort of BSG005 Clinical Trial, Shows Promising Potential in Drug-Resistant Fungal Infections 0,72 SEK | -0,83% | 0,46 MSEK

2024-10-07 08:30:00 Biosergen AB: Biosergen Completes Enrollment of First Cohort in BSG005 Proof-of-Concept Trial 0,50 SEK | +1,83% | 0,29 MSEK

2024-10-07 08:30:00 Biosergen AB: Biosergen slutför rekrytering av den första kohorten i BSG005 Proof-of-Concept-studien 0,50 SEK | +1,83% | 0,29 MSEK

2024-08-30 08:15:00 Biosergen AB: Biosergen publishes interim report for second quarter 2024 0,70 SEK | +41,70% | 0,48 MSEK

2024-08-30 08:00:00 Biosergen AB: Biosergen have completed treatment of the first patient with BSG005 0,70 SEK | +41,70% | 0,48 MSEK

2024-07-12 10:11:21 Biosergen AB: First Patient in Biosergen Clinical Trial Treating with BSG005 for Life Threatening Fungal Infection 0,39 SEK | +2,90% | 0,03 MSEK

2024-06-14 12:25:58 Bulletin from the annual general meeting on June 14, 2024 in Biosergen AB 0,34 SEK | +10,97% | 0,02 MSEK

2024-06-12 08:15:05 Biosergen AB: Biosergen to welcome two new board members based on election at the Annual General Meeting 0,31 SEK | 0,00% | 0,03 MSEK

2024-06-11 12:37:27 Biosergen AB: Biosergen receives the final permission required to test lead candidate BSG005 in patients with invasive fungal infection. 0,31 SEK | -10,17% | 0,31 MSEK

2024-05-31 08:30:00 Biosergen AB: Biosergen publishes interim report for first quarter 2024 0,33 SEK | +5,83% | 0,01 MSEK

2024-05-17 08:30:00 Notice of annual general meeting in Biosergen AB 0,30 SEK | -0,67% | 0,02 MSEK

2024-05-10 13:57:49 Biosergen AB: Biosergen publishes 2023 annual report 0,31 SEK | 0,00% | 0,02 MSEK

2024-04-16 08:46:55 Biosergen AB: Conversion of paid subscribed units and first day of trading with warrants of series TO3 0,45 SEK | -5,22% | 0,00 MSEK

2024-04-09 09:08:44 Biosergen AB: Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue 0,38 SEK | +11,01% | 0,02 MSEK

2024-03-26 17:00:00 Biosergen AB: Biosergen announces the outcome in the rights issue 0,44 SEK | -5,93% | 0,03 MSEK

2024-03-18 08:15:00 Biosergen AB: BioStock Investor Pitch: Biosergen 0,31 SEK | 0,00% | 0,01 MSEK

2024-03-15 08:35:00 Biosergen AB: Members of the board of directors and management subscribe in ongoing rights issue 0,31 SEK | +8,51% | 0,04 MSEK

2024-03-05 13:39:33 Biosergen AB: Biosergen publishes prospectus due to rights issue of units 0,59 SEK | -4,80% | 0,04 MSEK

2024-03-01 12:00:00 Bulletin from the extraordinary general meeting in Biosergen AB (publ) 0,41 SEK | -7,43% | 0,02 MSEK

2024-02-29 08:35:00 Biosergen AB: Biosergen publishes interim report for fourth quarter 2023 0,44 SEK | -0,67% | 0,03 MSEK

2024-02-12 13:07:25 Biosergen AB: Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection. 0,41 SEK | +7,69% | 0,18 MSEK

2024-01-30 21:00:00 Notice of Extraordinary general meeting in Biosergen AB 0,28 SEK | -32,66% | 0,33 MSEK

2024-01-30 18:30:00 Biosergen AB: Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan 0,28 SEK | -32,66% | 0,33 MSEK

2024-01-12 09:35:00 Biosergen AB: Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor 0,53 SEK | -3,76% | 0,26 MSEK

2023-12-12 13:45:32 Biosergen AB: Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy 0,64 SEK | +1,87% | 0,24 MSEK

2023-11-30 12:04:24 Biosergen AB: Biosergen publishes interim report for third quarter 2023 0,67 SEK | -2,56% | 0,06 MSEK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Biosergen

Kalender

Beskrivning

Biosergen

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden